NUVL
Nuvalent, Inc. NASDAQ Listed Jul 29, 2021$123.43
+0.06%
vs $123.36
Mkt Cap $9.0B
52w Low $72.16
100.0% of range
52w High $123.45
50d MA $105.64
200d MA $99.67
P/E (TTM)
-21.1x
EV/EBITDA
—
P/B
7.2x
Debt/Equity
0.0x
ROE
-34.1%
P/FCF
-32.6x
RSI (14)
60.00
ATR (14)
$3.05
Beta
1.31
50d MA
$105.64
200d MA
$99.67
Avg Volume
3.5M
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
One Broadway · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 104.26 | -0.1% | -1.8% | +2.8% | -0.7% | -1.9% | +2.6% | — |
| Feb 26, 2026 | AMC | -1.48 | -1.29 | +12.8% | 103.93 | -0.9% | -1.9% | -0.6% | -1.1% | +2.4% | -2.5% | — |
| Oct 30, 2025 | AMC | -1.39 | -1.70 | -22.3% | 98.17 | +1.7% | +1.2% | -6.3% | -2.2% | +1.2% | +4.1% | — |
| Aug 7, 2025 | AMC | -1.27 | -1.31 | -3.1% | 72.16 | -0.2% | +2.7% | +1.1% | +2.2% | +2.1% | -1.8% | — |
| May 8, 2025 | AMC | -1.14 | -1.18 | -3.5% | 71.60 | +0.7% | -2.4% | +5.4% | -3.0% | -0.6% | -0.0% | — |
| Feb 27, 2025 | AMC | -1.04 | -1.05 | -1.0% | 74.91 | -1.2% | +0.1% | -5.3% | +0.8% | +0.5% | +1.3% | — |
| Nov 12, 2024 | AMC | -0.93 | -1.28 | -37.0% | 90.99 | +0.6% | -0.7% | -0.2% | -3.7% | +0.9% | +3.8% | — |
| Aug 8, 2024 | AMC | -0.76 | -0.88 | -15.8% | 70.24 | +0.2% | -0.4% | +3.1% | -1.0% | -2.0% | +2.7% | — |
| May 9, 2024 | AMC | -0.67 | -0.69 | -3.0% | 67.52 | -1.2% | -3.0% | +0.9% | +2.9% | +5.4% | +1.3% | — |
| Feb 27, 2024 | AMC | -0.59 | -0.62 | -5.1% | 88.99 | -0.3% | -4.1% | -1.5% | +3.6% | -2.5% | -4.2% | — |
| Nov 14, 2023 | AMC | -0.59 | -0.59 | +0.0% | 58.81 | -2.1% | +0.3% | -1.6% | +2.9% | +1.0% | -0.6% | — |
| Aug 10, 2023 | AMC | -0.53 | -0.51 | +3.8% | 43.48 | -1.2% | -1.0% | -0.3% | -1.7% | -0.6% | -1.9% | — |
| May 11, 2023 | AMC | -0.51 | -0.44 | +13.7% | 40.09 | +7.2% | -1.7% | +3.4% | -1.9% | -1.2% | -1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 22 | Bernstein | Initiates | Outperform | $189 | $101.24 | $102.00 | +0.8% | +0.9% | +2.8% | +2.3% | +1.8% | +1.0% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $108.24 | $108.45 | +0.2% | -1.0% | +1.6% | -0.8% | -3.3% | -0.4% |
| Apr 8 | Wedbush | Maintains | Outperform → Outperform | — | $102.25 | $105.65 | +3.3% | +2.7% | -0.4% | -1.8% | +0.9% | +1.3% |
| Feb 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $103.93 | $102.96 | -0.9% | -1.9% | -0.6% | -1.1% | +2.4% | -2.5% |
| Dec 19 | JP Morgan | Maintains | Overweight → Overweight | — | $101.41 | $104.00 | +2.6% | +2.4% | +1.8% | -0.8% | +0.9% | -1.6% |
| Nov 18 | Baird | Maintains | Outperform → Outperform | — | $108.00 | $104.38 | -3.4% | -3.5% | +2.8% | +0.8% | -2.0% | +3.4% |
| Nov 18 | Guggenheim | Maintains | Buy → Buy | — | $108.00 | $104.38 | -3.4% | -3.5% | +2.8% | +0.8% | -2.0% | +3.4% |
| Nov 18 | Goldman Sachs | Maintains | Buy → Buy | — | $108.00 | $104.38 | -3.4% | -3.5% | +2.8% | +0.8% | -2.0% | +3.4% |
| Nov 17 | Stifel | Maintains | Buy → Buy | — | $96.50 | $93.30 | -3.3% | +11.9% | -3.5% | +2.8% | +0.8% | -2.0% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $96.50 | $93.30 | -3.3% | +11.9% | -3.5% | +2.8% | +0.8% | -2.0% |
| Nov 17 | Leerink Partners | Maintains | Outperform → Outperform | — | $96.50 | $93.30 | -3.3% | +11.9% | -3.5% | +2.8% | +0.8% | -2.0% |
| Oct 31 | UBS | Maintains | Buy → Buy | — | $98.17 | $99.85 | +1.7% | +1.2% | -6.3% | -2.2% | +1.2% | +4.1% |
| Oct 31 | Barclays | Maintains | Overweight → Overweight | — | $98.17 | $99.85 | +1.7% | +1.2% | -6.3% | -2.2% | +1.2% | +4.1% |
| Oct 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $93.39 | $94.95 | +1.7% | +4.6% | +3.6% | +1.7% | -4.7% | +1.2% |
| Sep 8 | Wedbush | Maintains | Outperform → Outperform | — | $80.89 | $80.77 | -0.1% | -1.3% | -1.4% | -0.3% | +4.7% | -2.1% |
| Jun 25 | Baird | Maintains | Outperform → Outperform | — | $76.88 | $77.60 | +0.9% | +2.9% | +0.1% | +0.7% | -4.2% | +2.2% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $75.98 | $76.56 | +0.8% | +1.2% | +2.9% | +0.1% | +0.7% | -4.2% |
| Jun 24 | Leerink Partners | Maintains | Outperform → Outperform | — | $75.98 | $76.56 | +0.8% | +1.2% | +2.9% | +0.1% | +0.7% | -4.2% |
| Mar 14 | UBS | Upgrade | Neutral → Buy | — | $74.48 | $77.83 | +4.5% | +3.4% | +0.0% | -0.5% | +1.2% | +0.1% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $74.98 | $74.62 | -0.5% | -5.3% | +0.8% | +0.5% | +1.3% | -2.6% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $75.99 | $76.53 | +0.7% | -0.2% | +3.2% | +3.9% | +2.9% | -1.8% |
| Nov 13 | BMO Capital | Maintains | Outperform → Outperform | — | $90.99 | $91.50 | +0.6% | -0.7% | -0.2% | -3.7% | +0.9% | +3.8% |
| Oct 4 | JP Morgan | Maintains | Overweight → Overweight | — | $103.50 | $105.27 | +1.7% | +1.4% | -1.5% | -0.9% | -1.1% | +1.1% |
| Sep 16 | BMO Capital | Maintains | Outperform → Outperform | — | $87.45 | $102.70 | +17.4% | +28.3% | -6.6% | -2.0% | +0.6% | +4.6% |
| Sep 16 | Wedbush | Maintains | Outperform → Outperform | — | $87.45 | $102.70 | +17.4% | +28.3% | -6.6% | -2.0% | +0.6% | +4.6% |
| Sep 16 | Guggenheim | Maintains | Buy → Buy | — | $87.45 | $102.70 | +17.4% | +28.3% | -6.6% | -2.0% | +0.6% | +4.6% |
| Sep 16 | Stifel | Maintains | Buy → Buy | — | $87.45 | $102.70 | +17.4% | +28.3% | -6.6% | -2.0% | +0.6% | +4.6% |
| Sep 9 | Wedbush | Maintains | Outperform → Outperform | — | $86.25 | $85.26 | -1.1% | +3.5% | -2.0% | -2.1% | -4.6% | +7.1% |
| Sep 4 | JP Morgan | Maintains | Overweight → Overweight | — | $83.64 | $83.08 | -0.7% | +1.1% | +0.4% | +1.5% | +3.5% | -2.0% |
| Jul 10 | Stifel | Maintains | Buy → Buy | — | $73.63 | $75.12 | +2.0% | +1.2% | +4.7% | +0.8% | +3.6% | +3.1% |
| May 17 | Wedbush | Maintains | Outperform → Outperform | — | $72.64 | $73.77 | +1.6% | -2.4% | +0.1% | -1.7% | +0.1% | -4.5% |
| Apr 1 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $75.09 | $77.14 | +2.7% | +2.7% | -4.8% | +0.8% | -2.8% | -2.4% |
| Mar 6 | JP Morgan | Maintains | Overweight → Overweight | — | $81.42 | $82.17 | +0.9% | +3.7% | -1.2% | +1.1% | -0.9% | +4.0% |
| Feb 28 | BMO Capital | Maintains | Outperform → Outperform | — | $88.99 | $88.74 | -0.3% | -4.1% | -1.5% | +3.6% | -2.5% | -4.2% |
| Oct 19 | BMO Capital | Maintains | Outperform → Outperform | — | $53.05 | $53.40 | +0.7% | -3.8% | +0.1% | -1.5% | +3.2% | +1.8% |
| Oct 5 | BMO Capital | Maintains | Outperform → Outperform | — | $57.51 | $58.35 | +1.5% | +8.5% | +3.4% | -3.3% | -1.5% | -0.4% |
| Oct 5 | JP Morgan | Maintains | Overweight → Overweight | — | $57.51 | $58.35 | +1.5% | +8.5% | +3.4% | -3.3% | -1.5% | -0.4% |
| Jul 20 | Wedbush | Maintains | Outperform → Outperform | — | $44.52 | $44.61 | +0.2% | +1.0% | -0.5% | +2.9% | +0.2% | +1.9% |
| Jun 23 | JP Morgan | Maintains | Overweight → Overweight | — | $42.07 | $42.12 | +0.1% | +4.2% | -6.1% | +3.5% | +0.6% | -0.1% |
| Jan 18 | Wedbush | Maintains | Outperform → Outperform | — | $33.30 | $34.66 | +4.1% | -0.9% | -0.8% | -5.7% | -0.0% | +5.9% |
| Jun 24 | BMO Capital | Maintains | Outperform → Outperform | — | $12.77 | $13.19 | +3.3% | +6.4% | -0.6% | -1.3% | +4.6% | -2.8% |
| Aug 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.02 | $27.46 | +1.6% | +7.3% | +2.1% | +4.5% | +5.8% | +6.0% |
| Aug 23 | JP Morgan | Maintains | Overweight → Overweight | — | $27.02 | $27.46 | +1.6% | +7.3% | +2.1% | +4.5% | +5.8% | +6.0% |
| Aug 23 | TD Cowen | Maintains | Outperform → Outperform | — | $27.02 | $27.46 | +1.6% | +7.3% | +2.1% | +4.5% | +5.8% | +6.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Noci Darlene | Chief Development Officer | Sell | 20,000 | $122.81 | $2.5M | 58,117 | -0.16% | +0.06% |
| Jun 8, 2026 | Porter James Richard | President and CEO | Sell | 3,036 | $89.63 | $272K | 324,879 | +0.08% | -0.02% |
| Jun 8, 2026 | Porter James Richard | President and CEO | Sell | 14,469 | $88.79 | $1.3M | 327,915 | +0.08% | -0.02% |
| Jun 8, 2026 | Porter James Richard | President and CEO | Sell | 12,495 | $87.97 | $1.1M | 342,384 | +0.08% | -0.02% |
| Jun 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 200 | $103.84 | $21K | 85,533 | +4.26% | +0.08% |
| Jun 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 279 | $101.79 | $28K | 85,733 | +4.26% | +0.08% |
| Jun 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 2,588 | $100.65 | $260K | 86,012 | +4.26% | +0.08% |
| Jun 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 3,133 | $99.86 | $313K | 88,600 | +4.26% | +0.08% |
| Jun 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 1,200 | $98.57 | $118K | 91,733 | +4.26% | +0.08% |
| Jun 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 900 | $97.68 | $88K | 92,933 | +4.26% | +0.08% |
| Jun 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 2,170 | $95.99 | $208K | 93,833 | +4.26% | +0.08% |
| Jun 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 960 | $94.87 | $91K | 96,003 | +4.26% | +0.08% |
| May 28, 2026 | Noci Darlene | Chief Development Officer | Sell | 100 | $109.76 | $11K | 58,117 | -1.78% | -2.70% |
| May 28, 2026 | Noci Darlene | Chief Development Officer | Sell | 1,500 | $109.30 | $164K | 58,217 | -1.78% | -2.70% |
| May 28, 2026 | Noci Darlene | Chief Development Officer | Sell | 1,178 | $108.01 | $127K | 59,717 | -1.78% | -2.70% |
| May 28, 2026 | Noci Darlene | Chief Development Officer | Sell | 1,422 | $107.33 | $153K | 60,895 | -1.78% | -2.70% |
| May 28, 2026 | Noci Darlene | Chief Development Officer | Sell | 1,300 | $106.26 | $138K | 62,317 | -1.78% | -2.70% |
| May 28, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 1,669 | $109.30 | $182K | 59,634 | -1.78% | -2.70% |
| May 28, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 900 | $108.14 | $97K | 61,303 | -1.78% | -2.70% |
| May 28, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 1,530 | $107.45 | $164K | 62,203 | -1.78% | -2.70% |
| May 28, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 1,401 | $106.32 | $149K | 63,733 | -1.78% | -2.70% |
| May 4, 2026 | Porter James Richard | President and CEO | Sell | 2,111 | $102.88 | $217K | 324,879 | -1.78% | +2.61% |
| May 4, 2026 | Porter James Richard | President and CEO | Sell | 17,353 | $102.10 | $1.8M | 326,990 | -1.78% | +2.61% |
| May 4, 2026 | Porter James Richard | President and CEO | Sell | 7,429 | $101.48 | $754K | 344,343 | -1.78% | +2.61% |
| May 4, 2026 | Porter James Richard | President and CEO | Sell | 1,408 | $99.77 | $140K | 351,772 | -1.78% | +2.61% |
| May 4, 2026 | Porter James Richard | President and CEO | Sell | 1,699 | $98.54 | $167K | 353,180 | -1.78% | +2.61% |
| May 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 124 | $99.97 | $12K | 85,533 | +2.75% | -1.92% |
| May 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 7,434 | $99.29 | $738K | 85,657 | +2.75% | -1.92% |
| May 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 3,872 | $98.42 | $381K | 93,091 | +2.75% | -1.92% |
| Apr 30, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 1,082 | $99.57 | $108K | 59,634 | +3.61% | +2.81% |
8-K
Nuvalent, Inc. -- 8-K Filing
Jun 18
8-K
Nuvalent, Inc. -- 8-K Filing
Jun 9
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I cannot provide a meaningful analysis because the filing content provided is incomplete—it contains only technical HTML/XML metadata without any actual material event details or substantive disclosure for Nuvei (NUVL).
Apr 7
8-K
Nuvalent, Inc. -- 8-K Filing
Nuvalent (NUVL) reported 2025 financial results and reaffirmed key pipeline milestones while advancing commercial preparations for potential U.S. product launches in its targeted cancer therapy programs.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Deerfield Management Company, L.p. | 17,248,450 | $1.8B | — | Mar 2026 |
| 2 | Fmr Llc | 9,274,959 | $950M | Reduced | Mar 2026 |
| 3 | Jpmorgan Chase & Co | 3,088,349 | $299M | Added | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 2,500,907 | $256M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 2,428,488 | $249M | New | Mar 2026 |
| 6 | Janus Henderson Group Plc | 1,237,779 | $127M | New | Mar 2026 |
| 7 | Bellevue Group Ag | 1,053,268 | $108M | Added | Mar 2026 |
| 8 | Braidwell Lp | 821,406 | $83M | Reduced | Dec 2025 |
| 9 | Woodline Partners Lp | 610,459 | $63M | — | Mar 2026 |
| 10 | Morgan Stanley | 534,778 | $54M | Reduced | Dec 2025 |
| 11 | Hood River Capital Management Llc | 479,998 | $49M | Added | Mar 2026 |
| 12 | Franklin Resources Inc | 434,742 | $45M | Added | Mar 2026 |
| 13 | Northern Trust Corp | 429,373 | $44M | Added | Mar 2026 |
| 14 | Invesco Ltd. | 408,285 | $42M | Reduced | Mar 2026 |
| 15 | Ubs Group Ag | 363,098 | $37M | Reduced | Mar 2026 |
| 16 | Candriam S.c.a. | 358,013 | $36M | Added | Dec 2025 |
| 17 | Pictet Asset Management Holding Sa | 355,681 | $36M | Reduced | Dec 2025 |
| 18 | Tri Locum Partners Lp | 308,506 | $32M | New | Mar 2026 |
| 19 | Silverarc Capital Management, Llc | 311,430 | $31M | Reduced | Dec 2025 |
| 20 | Jones Hill Capital Lp | 300,830 | $31M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$8.97B
Enterprise Value
$7.60B
P/E (TTM)
-21.10x
Forward P/E
—
PEG Ratio
-0.35x
P/B
7.19x
P/S
—
P/FCF
-32.60x
EV/EBITDA
—
Shares Out
72.7M
Financials (TTM)
Revenue
$0
Net Income
-$425.4M
EBITDA
-$10.5M
Free Cash Flow
-$275.2M
Op Cash Flow
-$275.2M
EPS Basic
$-5.85
EPS Diluted
$-5.85
EPS Forward
$-5.56
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$1.41B
Total Liab.
$164.4M
Total Equity
$1.25B
Cash
$1.37B
LT Debt
$0
Book Value/Sh
$17.17
Debt/Equity
0.00x
Current Ratio
15.27
Quick Ratio
15.27
Returns & Growth
ROE
-34.1%
ROA
-30.1%
ROIC
-31.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
-48.9%
Price Returns
2W
+5.7%
1M
+10.1%
3M
+8.3%
6M
+1.0%
12M
+48.0%
Technicals
52W High
$123.45
52W Low
$72.16
50d MA
$105.64
200d MA
$99.67
RSI (14)
60.00
ATR (14)
$3.05
Beta
1.31
Avg Volume
3.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$139.14
High
$155.00
Low
$120.00
Median
$140.00
Data updated apr 26, 2026 4:11pm
· Source: financialmodelingprep.com